US-based medical technology company NeuroPace has launched its Next Gen RNS System to treat seizures in patients suffering from refractory epilepsy.
The next generation system is designed as a closed loop brain-responsive neurostimulation device based on a brain-computer interface that can continuously monitor brain waves.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It identifies the ‘seizure onset fingerprint’ unique to individual patients and automatically sends imperceptible electrical pulses even before the occurrence of seizures.
In its new device, NeuroPace increased battery life from 3.9 years to 8.4 years under medium stimulation environments, to ensure fewer interruptions for patients.
The Next Gen RNS System also features additional memory to enable review of more brain activity data.
NeuroPace CEO Frank Fischer said: “NeuroPace revolutionised epilepsy therapy in 2013 with the introduction of the world’s first closed loop, brain-responsive neuromodulation system-the only device that applies brain-computer interface technology to successfully treat refractory focal onset epilepsy.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We have maintained our relentless focus on product innovation, and are excited to make the Next Gen RNS System with twice the longevity and twice the memory in the same size device available to our physician customers and their patients.”
The RNS System consists of a neurostimulator, a remote monitor for patients to upload their data and a RNS Tablet.
It is accompanied by a Patient Data Management System (PDMS) for physicians to remotely track patient’s electrographic data and programme the device to personalise therapy based on individual brain patterns.
The system is an adjunctive therapy for adults with refractory, focal onset seizures with not more than two epileptogenic foci.
